KRAS and cancer: We finally extended our observations to other cancer types by measuring circulating PAF‐AH activity in mice either subcutaneously injected with LLC cells or carrying genetic mutations of genes coding for the oncogene KRAS and tumour suppressor TRP53 in the pancreas, leading to spontaneous tumourigenesis (KPC mice).